国家“重大新药创制”科技重大专项重点关注靶点分析解读——受体酪氨酸激酶c-Met

Analysis of Important Targets in National Key Subject of Drug Innovation——Receptor Tyrosine Kinase c-Met

c-Met为一种由原癌基因MET编码的跨膜受体酪氨酸激酶,是肝细胞生长因子的受体,与多种癌症的不良预后有关。近年来,c-Met抑制剂作为一种对抗癌症的有效策略备受关注。结合汤森路透数据库资源——Thomson Reuters Integrity和Cortellis for Competitive Intelligence,对c-Met在疾病中的作用、相关药物研究进展、适应证、研发机构、交易、专利、文献等情报进行了数据层面的分析。

c-Met is a transmembrane receptor tyrosine kinase that is encoded by MET proto-oncogene. It serves as a receptor for hepatocyte growth factor （HGF）. The abnormal level of c-Met is correlated with poor prognosis in a number of cancers. As an effective therapeutic strategy, the c-Met inhibitors have been paid much attention recently. The intelligence of c-Met, including role in diseases, research progress of related drugs, indications, originators, deals, patents and references, have been analyzed by Thomson Reuters Integrity and Cortellis for Competitive Intelligence in this paper.